Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stable dust extract is an investigational biologic agent derived from the environmental dust of traditional cattle stables, developed to harness the "farm effect"—the observation that children raised in farming environments have a lower prevalence of asthma and allergies. The extract is a complex mixture of microbial components, including bacterial endotoxins (LPS) and other pathogen-associated molecular patterns (PAMPs). Its mechanism of action involves the modulation of the innate immune system through the activation of pattern recognition receptors, such as Toll-like receptors (TLR2 and TLR4), on airway epithelial cells and dendritic cells. This stimulation is thought to promote a Th1-biased immune environment and regulatory T-cell activity, thereby preventing the Th2-driven allergic sensitization and chronic airway inflammation associated with asthma. It is primarily being investigated as a preventive intranasal treatment for infants and children at high risk for atopic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stable dust extract.